A.forall Announces Launch of a Generic Version of Pyridostigmine Bromide Syrup

11 Dec 2023
www.biospace.com
Drug Approval
MINNETONKA, Minn.--(BUSINESS WIRE)-- Milla Pharmaceuticals Inc., an A.forall company, announced that its partner, Acella Pharmaceuticals LLC, has just commercialized its Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Mestinon® (Pyridostigmine Bromide Syrup) 60 mg/5mL. This press release features multimedia. View the full release here: Pyridostigmine Bromide Syrup is indicated for symptomatic treatment of myasthenia gravis. Myasthenia gravis is a neuromuscular disorder primarily characterized by muscle weakness and rapid muscle fatigue. This achievement marks the third ANDA commercialization for Milla Pharmaceuticals Inc. and the fourth for an A.forall product in the U.S. market. “After our rebranding into A.forall, uniting our teams and businesses under one single name that embodies our joint mission of making affordable medicines available to all, this fourth U.S. launch is the next big milestone for our group in 2023, which was already a very successful year for us,” commented A.forall CEO Filip Van de Vliet, “a year in which we also received two so-called first cycle approvals from FDA. With all other projects in our pipeline, our team looks forward to continuing that trend and turning our mission into reality.” Acella is excited to partner with Milla Pharmaceuticals on the commercialization of the Pyridostigmine Bromide Syrup. “This product continues our long tradition of supplying affordable generic formulations and furthers our commitment to neurology,” stated Art Deas, CEO of Alora Pharmaceuticals parent company of Acella Pharmaceuticals, LLC. About A.forall We Make Affordable Medicines Available To All: we develop value-added generic pharmaceuticals, solve product shortages and fill unmet medical needs so that patients can continue their treatment. At the same time, we are reducing costs to the healthcare system and increasing customer convenience for a more sustainable world. More info: About – A.forall About Milla Pharmaceuticals Inc. Milla Pharmaceuticals Inc., an A.forall company, is engaged in the development, licensing, acquisition, and commercialization of generic prescription drugs for the U.S. market focused on niche injectable and solution products for hospitals and clinics. More info: About - Milla Pharmaceuticals Inc. About Acella Pharmaceuticals LLC The mission at Acella, an Alora Pharmaceuticals company, is to deliver quality products at affordable prices – bringing value to their customer base while providing savings and choice to patients nationwide. They are committed to developing, manufacturing, and distributing products that meet the highest quality standards through compliance with all applicable regulatory requirements. More info: Acella Pharmaceuticals LLC View source version on businesswire.com: Contacts Erik Lazarich President Milla Pharmaceuticals Inc., an A.forall company Mobile: +1 651-231-1042 │ Office: +1 952-449-5154 │ email: erik.lazarich@millapharma.com Source: Milla Pharmaceuticals Inc. Smart Multimedia Gallery Photo Logo Photo View this news release and multimedia online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.